Historically,most payers have only covered one round of BRCA1/2 GT for eligiblepatients; therefore, most studies focused on retesting after first-lineBRCA1/2 analysis alone (“BRCA1/2retesting”).[3, 5, 18–27] The pathogenic/likely pathogenic variant(PV/LPV) detection rate in BRCA1/2 retesting studies ranged from3-11% in cohorts unselected for a personal history of cancer, and 5-13% in thosewith breast or ovarian cancer.[18–27] Few studies so farhave examined outcomes of retesting patients whose first-line testing included genesbeyond BRCA1/2.[28–30]. This evidence concerns the gene BRCA1 and ovarian cancer.